NEW ZEALAND GAZETTE, No. 11

2 FEBRUARY 2012

when sold in the manufacturer’s original pack containing not more than 14 days’ supply

Nystatin; for dermal use except when sold in practice by a podiatrist registered with the Podiatrists Board

Omeprazole; in divided solid dosage forms for oral use containing 20 milligrams or less with a maximum daily dose of 20 milligrams for the short-term symptomatic relief of gastric reflux-like symptoms in sufferers aged 18 years and over when sold in the manufacturer’s original pack containing not more than 28 dosage units

Pantoprazole; in divided solid dosage forms for oral use containing 20 milligrams or less with a maximum daily dose of 20 milligrams for the short-term symptomatic relief of gastric reflux-like symptoms in sufferers aged 18 years and over when sold in the manufacturer’s original pack containing not more than 28 dosage units

Ranitidine; in medicines for the symptomatic relief of heartburn, dyspepsia and hyperacidity or to be used on the recommendation of a registered medical practitioner when sold in the manufacturer’s original pack containing not more than 14 days’ supply; except in medicines containing 150 milligrams or less per dose unit when sold in the manufacturer’s original pack containing not more than 7 days’ supply

Terbinafine; for dermal use except in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board

Tioconazole; for dermal use except in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board

Medicines for General Sale

Please note that the following medicines are now available for general sale.

Amorolfine; in preparations for the treatment of tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board

C1 esterase inhibitors

Cetirizine; in divided solid dosage forms for oral use containing 10 milligrams or less of cetirizine hydrochloride per dose form for the treatment of seasonal allergic rhinitis when sold in the manufacturer’s original pack containing not more than 5 days’ supply

Ciclopirox; for external use in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board

Clotrimazole; for external use in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board

Diclofenac; in preparations for external use other than for the treatment of solar keratosis

Econazole; for dermal use in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board

Factor VIII inhibitor bypassing fraction

Fexofenadine; for the treatment of seasonal allergic rhinitis in capsules containing 60 milligrams or less of fexofenadine hydrochloride or in tablets containing 120 milligrams or less of fexofenadine hydrochloride with a maximum daily dose of 120 milligrams when sold in the manufacturer’s original pack containing not more than 10 dosage units

Guaiphenesin; for oral use in medicines containing 2% or less or 200 milligrams or less per dose form; for oral use in modified release form with a maximum recommended daily dose of not more than 2.4 grams when sold in the manufacturer’s original pack containing not more than 10 days’ supply

Human protein C

Ibuprofen; for external use; in divided solid dosage forms for oral use containing 200 milligrams or less per dose form with a recommended daily dose of not more than 1.2 grams and when sold in the manufacturer’s original pack containing not more than 25 dose units per pack

Isoconazole; for dermal use when sold in practice by a podiatrist registered with the Podiatrists Board

Ketoconazole; for dermal use in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board; in medicines for treatment of the scalp containing 1% or less

Loratadine; in divided solid dosage forms for oral use containing 10 milligrams or less per dose form for the treatment of seasonal allergic rhinitis when sold in the manufacturer’s original pack containing not more than 5 days’ supply

Miconazole; for external use in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board

Nystatin; for dermal use when sold in practice by a podiatrist registered with the Podiatrists Board

Ranitidine; in medicines containing 150 milligrams or less per dose unit when sold in the manufacturer’s original pack containing not more than 7 days’ supply

Terbinafine; for dermal use in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board

Tioconazole; for dermal use in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board

Dated this 27th day of January 2012.

DR PAT TUOHY, Acting Chief Medical Officer, Clinical Leadership, Protection and Regulation Business Unit, Ministry of Health.

go561

Labour

Health and Safety in Employment Act 1992

Approval to Revoke Approved Code of Practice for Demolition

Notice is given that the Minister of Labour has given approval to revoke the Approved Code of Practice for Demolition, pursuant to section 20(1)(b) of the Health and Safety in Employment Act 1992.

The Department of Labour has consulted with members of the construction and demolition industries and the public regarding the revocation of this approved code.

The revocation will come into effect on Thursday 1 March 2012.

The approved code has been replaced by the document Best Practice Guidelines for Demolition in New Zealand, published by the New Zealand Demolition and Asbestos Association in November 2011.

This guideline can be viewed at

www.osh.govt.nz/order/catalogue/demolition.shtml

and can also be purchased from the New Zealand Demolition and Asbestos Association at

www.demolition-asbestos.co.nz

Dated at Wellington this 2nd day of February 2012.